Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

6(66.7%)

Phase 3

2(22.2%)

N/A

1(11.1%)

9Total

Phase 2(6)

Phase 3(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT02139904Phase 2Completed

Vinorelbine in Mesothelioma

Role: lead

NCT01817257Phase 2Terminated

Anticoagulation Length in Cancer Associated Thrombosis

Role: collaborator

NCT01099423Phase 3Unknown

Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer

Role: collaborator

NCT01344005Not ApplicableUnknown

Standard Medical Care or Urgent Chest X-ray in Diagnosing Lung Cancer in Smokers With Chest Symptoms Who Are Older Than 60 Years

Role: lead

NCT00326820Phase 3Unknown

Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer

Role: lead

NCT01569919Phase 2Unknown

A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma

Role: lead

NCT00509561Phase 2Unknown

Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer

Role: lead

NCT01097317Phase 2Unknown

First-Line Chemotherapy With or Without Neuromuscular Electrical Stimulation in Treating Patients With Non-Small Cell Lung Cancer

Role: lead

NCT01196403Phase 2Unknown

Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer

Role: lead

All 9 trials loaded